Full-Time
Associate Director
Clinical Scientist
Posted on 6/3/2024
Verve Therapeutics
201-500 employees
Develops gene editing therapies for cardiovascular disease
Senior, Expert
Boston, MA, USA
- Advanced degree in life sciences (e.g. PhD, PharmD, MD, Masters etc.) with 5+ years of relevant experience including 3 years of clinical development experience
- Familiarity with key clinical study documents
- Experience with analysis and review of clinical data
- Working knowledge of biostatistics, GCP, and regulatory requirements for clinical studies
- Experience working with CROs and external vendors
- Strong attention to detail and organizational skills
- Exceptional verbal and written communication skills
- Ability to build strong relationships and work effectively with cross-functional teams
- Partners with other clinical scientists and medical monitor on oversight of clinical trial activities, including safety reviews and site interactions
- Organize and lead process for review of potential patients for study participation
- Review, analyze, and interpret emerging clinical trial data
- Liase with the broader clinical development team at Verve (clinical operations, data management, and regulatory teams)
- Contribute to authoring key study and regulatory documents (e.g. protocol, ICF, study manuals)
- Leads internal meetings to review topics and develop mitigation plans
- Contribute to the development of presentations emerging from clinical studies
- Ensure compliance of all activities with ICH/GCP guidelines, applicable regulatory requirements, and Verve SOPs
- Other duties as assigned
Verve Therapeutics focuses on developing gene editing treatments for cardiovascular disease. Their approach involves creating single-course therapies that aim to provide lasting solutions rather than ongoing treatments. The company specifically targets the PCSK9 and ANGPTL3 genes, which are known to help lower blood lipid levels. This focus on gene editing sets Verve apart from traditional therapies that require continuous management. The goal of Verve Therapeutics is to offer potentially curative options for patients with cardiovascular conditions, improving their long-term health outcomes.
Company Stage
IPO
Total Funding
$419.3M
Headquarters
Cambridge, Massachusetts
Founded
2018
6 month growth
↑ 8%1 year growth
↑ 9%2 year growth
↑ 37%
Simplify's Take
What believers are saying
- Significant financial backing, including a $63 million Series A2 financing and $60 million from Eli Lilly, positions Verve for robust R&D and clinical trial activities.
- The potential for a 'one-and-done' treatment for cardiovascular diseases could revolutionize the field and offer a high-impact, life-saving solution.
- Early-stage success and strategic partnerships could lead to lucrative licensing deals and further investment opportunities.
What critics are saying
- The clinical-stage nature of Verve's therapies means they are still years away from potential market approval, posing a long-term risk.
- The recent stock price drop following a public offering indicates market volatility and potential investor uncertainty.
What makes Verve Therapeutics unique
- Verve Therapeutics focuses on gene-editing therapies specifically for cardiovascular diseases, setting it apart from other CRISPR-based companies that target a broader range of conditions.
- Their 'one-and-done' gene-editing approach aims to provide a single, curative treatment, which is a significant advantage over traditional, ongoing therapies.
- Partnerships with major pharmaceutical companies like Eli Lilly enhance their credibility and provide substantial financial and research support.
Help us improve and share your feedback! Did you find this helpful?